StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TWSTBullishCorporate Developmentsnews
High materiality8/10

Twist Bioscience Misses Earnings but Raises Revenue Guidance

May 4, 2026, 2:08 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The increase in sales guidance and strong revenue growth are positive signals often leading to improved stock performance, despite the earnings miss. Historical context shows similar increases previously resulted in stock rallies.

AI summary

What happened, with direct paths to the underlying reporting

Twist Bioscience reported an adjusted loss that missed expectations, but its revenue surpassed forecasts, indicating strong growth potential. The company raised its fiscal 2026 sales guidance, reflecting positive momentum across its portfolio and expanded capabilities in AI-enabled drug discovery.

  • TWST reported a 59-cent loss, missing consensus expectations.
  • Sales of $110.72 million beat estimates of $107.66 million.
  • DNA Synthesis and Protein Solutions revenue grew 28% to $53.3 million.
  • Guidance raised for fiscal 2026 sales to $442 million-$447 million.
  • Settlement reached for $17.1 million in a class action lawsuit.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event